A randomized, double-blind study comparing 5 days oral gemifloxacin with 7 days oral levofloxacin in patients with acute exacerbation of chronic bronchitis S Sethi, C Fogarty, A Fulambarker Respiratory Medicine Volume 98, Issue 8, Pages 697-707 (August 2004) DOI: 10.1016/j.rmed.2004.03.028
Figure 1 Per-patient bacteriological response in the clinical PP and ITT populations at the key timepoints, ■ Gemifloxacin, clinical PP: end of therapy, n=40; follow-up, n=37; long-term follow-up, n=36. ITT (all timepoints): n=44, □ Levofloxacin, clinical PP: end of therapy, n=52; follow-up, n=49; long-term follow-up, n=44. ITT (all timepoints): n=60. Respiratory Medicine 2004 98, 697-707DOI: (10.1016/j.rmed.2004.03.028)